Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Blood (2022) 140 (5): 504–515.

https://doi.org/10.1182/blood.2022015601

Published: 2022

Includes: Supplemental data

Journal Articles

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Paolo Strati, Preetesh Jain, Ralph J. Johnson, Sheryl Forbes, Lei Feng, Felipe Samaniego, Maria A. Rodriguez, Luis E. Fayad, Fredrick Hagemeister, Jason Westin, Michael Wang, Sattva S. Neelapu, Loretta J. Nastoupil, Nathan H. Fowler

Blood (2021) 137 (8): 1124–1129.

https://doi.org/10.1182/blood.2020007994

Published: 2021

Includes: Supplemental data

Journal Articles

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Michael (Luhua) Wang, MD, Fredrick Hagemeister, MD, Jason R. Westin, MD, Luis Fayad, MD, Felipe Samaniego, MD, Francesco Turturro, MD, Wendy Chen, Liang Zhang, MD PhD, Maria Badillo, BS, Maria DeLa Rosa, Alicia Addison, Larry W. Kwak, MD PhD, Jorge E. Romaguera, MD

Blood (2014) 124 (21): 627.

https://doi.org/10.1182/blood.V124.21.627.627

Published: 2014

Journal Articles

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Blood (2012) 119 (18): 4123–4128.

https://doi.org/10.1182/blood-2012-01-405456

Published: 2012

Includes: Supplemental data

Journal Articles

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Yasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, Luis E. Fayad, Michelle Fanale, Jorge Romaguera, Anas Younes

Blood (2012) 119 (9): 2171–2172.

https://doi.org/10.1182/blood-2011-11-391037

Published: 2012

Journal Articles

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Felipe Samaniego, MD, Jillian F Wise, BS, Luis Fayad, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Vijairam Selvaraj, MD, David M. Goldenberg, ScD, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD

Blood (2011) 118 (21): 1796.

https://doi.org/10.1182/blood.V118.21.1796.1796

Published: 2011

Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD

Blood (2011) 118 (21): 3718.

https://doi.org/10.1182/blood.V118.21.3718.3718

Published: 2011

Journal Articles

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Nicolas Batty, MD, Elham Ghonimi, MD, Lei Feng, PhD, Anas Younes, MD, Rodriguez Alma, MD, Elizabeth Wager, MD, Fernando Martinez, MD, MPH, Michael Wang, MD, Peter McLaughlin, MD, Nathan Fowler, MD, Fredrick Hagemeister, MD

Blood (2010) 116 (21): 3357.

https://doi.org/10.1182/blood.V116.21.3357.3357

Published: 2010

Journal Articles

Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy

Grace-Julia Okoroji, Leandro de Padua Silva, Rima M Saliba, Martin Korbling, McLaughlin Peter, Chitra Hosing, Paolo Anderlini, Amin Alousi, Marcos de Lima, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Luis Fayad, Felipe Samaniego, MD, MPH, Nathan Fowler, Richard Champlin, Fredrick Hagemeister, Issa F Khouri

Blood (2010) 116 (21): 3510.

https://doi.org/10.1182/blood.V116.21.3510.3510

Published: 2010

Journal Articles

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Deborah A. Thomas, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Rebecca Garris, BA, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 1781.

https://doi.org/10.1182/blood.V116.21.1781.1781

Published: 2010

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD

Blood (2010) 116 (21): 3964.

https://doi.org/10.1182/blood.V116.21.3964.3964

Published: 2010

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Michelle A. Fanale, MD, Chao-Ming Lai, APN, Peter McLaughlin, MD, Jorge Romaguera, MD, Luis Fayad, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, MPH, Maria Alma Rodriguez, MD, Sattva S. Neelapu, Jatin J Shah, MD, Larry Kwak, Wenli Dong, Valerie Reed, MD, Bouthaina S. Dabaja, MD, Uday Popat, MD, Anas Younes, MD

Blood (2010) 116 (21): 2812.

https://doi.org/10.1182/blood.V116.21.2812.2812

Published: 2010

Journal Articles

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Amanda R Copeland, MS, Yumei Cao, MD, Michelle Fanale, M.D., Luis Fayad, MD, Peter McLaughlin, Barbara Pro, MD, Fredrick Hagemeister, Jorge Romaguera, MD, Felipe Samaniego, MD, Alma Rodriguez, MD, Anas Younes, MD

Blood (2009) 114 (22): 1680.

https://doi.org/10.1182/blood.V114.22.1680.1680

Published: 2009

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Journal Articles

Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).

Issa F Khouri, M.D., Roland Bassett, Barry Samuels, Farzaneh Maadani, Grace-Julia Okoroji, Robyn Harrell, Martin Korbling, Leandro de Padua Silva, Amin Alousi, Chitra Hosing, Sergio Giralt, Marcos de Lima, Paolo Anderlini, Uday Popat, Rosamar Valverde, Yvonne Hsu, Fredrick Hagemeister, Peter McLaughlin, L. Jeffrey Medeiros

Blood (2008) 112 (11): 1140.

https://doi.org/10.1182/blood.V112.11.1140.1140

Published: 2008

Journal Articles

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

Blood (2008) 111 (12): 5530–5536.

https://doi.org/10.1182/blood-2008-01-136242

Published: 2008

Journal Articles

Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Martin Korbling, MD, Chitra Hosing, MD, Luis Fayad, MD, Ming S. Lee, MD, Felipe Samaniego, MD, Barry I. Samuels, MD, Daniel Couriel, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Richard E. Champlin, MD

Blood (2007) 110 (11): 485.

https://doi.org/10.1182/blood.V110.11.485.485

Published: 2007

Journal Articles

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Luis Fayad, MD, Barbara Pro, MD, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Michael Wang, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD, Maria A. Rodriguez, MD

Blood (2007) 110 (11): 1285.

https://doi.org/10.1182/blood.V110.11.1285.1285

Published: 2007

Journal Articles

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Maria Alma Rodriguez, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Romaguera, MD, Larry Kwak, MD, Ph.D., Luis Fayad, MD, Xuelin Huang, Ph.D, Jean Bernard Durand, MD

Blood (2007) 110 (11): 4468.

https://doi.org/10.1182/blood.V110.11.4468.4468

Published: 2007

NARROW

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up.

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only